24 . 04 .2025
Press release
Galderma delivers record first quarter net sales of 1.129 billion USD, including strong performance from two launches with blockbuster potential, and confirms full-year guidance
21 . 03 .2025
Press release
Galderma publishes its 2024 Annual Report and the invitation to its first Annual General Meeting
06 . 03 .2025
Press release
Galderma delivers 2024 record net sales of 4.410 billion USD, up 9.3% year-on-year at constant currency1, and record Core EBITDA of 1.031 billion USD, while preparing to accelerate its growth trajectory into 2025 and beyond
14 . 02 .2025
Press release
Galderma’s Nemluvio® (nemolizumab) approved in the European Union for moderate-to-severe atopic dermatitis and prurigo nodularis
14 . 12 .2024
Press release
Galderma Receives U.S. FDA Approval for Nemluvio® (Nemolizumab) for Patients with Moderate-to-Severe Atopic Dermatitis
24 . 10 .2024
Press release
Galderma delivers record net sales of 3.259 B USD in the first nine months of 2024, demonstrates significant innovation progress, confirms and narrows its full year net sales guidance
13 . 08 .2024
Press release
Galderma receives U.S. FDA approval for Nemluvio® (nemolizumab) for adult patients living with prurigo nodularis
05 . 08 .2024
Press release
Galderma to pursue a new scientific partnership with L’Oréal to further advance its category leadership in dermatology
30 . 07 .2024
Press release
Galderma’s Relfydess™ (RelabotulinumtoxinA) receives positive decision for use in Europe
25 . 07 .2024
Press release
Galderma delivers record net sales of 2.2 billion USD and 10.8% year-on-year growth at constant currency for the first half of 2024